アブストラクト
| Title | BRAF変異陽性大腸癌の新たな治療戦略 |
|---|---|
| Subtitle | 特別寄稿 |
| Authors | 川上尚人*1, 緒方壮太*2 |
| Authors (kana) | |
| Organization | *1近畿大学医学部・内科学教室腫瘍内科部門, *2小野薬品工業株式会社 |
| Journal | 癌と化学療法 |
| Volume | 48 |
| Number | 6 |
| Page | 787-795 |
| Year/Month | 2021 / 6 |
| Article | 報告 |
| Publisher | 癌と化学療法社 |
| Abstract | 「要旨」近年, 大腸癌診療では採取した腫瘍組織・腫瘍細胞を用いて遺伝子レベルの解析を行い, 治療方針の決定に役立てるプレシジョン・メディシンが進みつつある. しかし, BRAF変異陽性大腸癌では治療選択のための検査は行われているものの, BRAFを標的とした薬剤が承認されておらず, プレシジョン・メディシンの目的を達することができていなかった. また, BRAF変異陽性大腸癌に特化した治療が確立されていないなか, 既存の薬物治療の効果は低く, 予後は極めて不良であった. そのため, BRAF変異陽性大腸癌に特異的な新たな治療選択が必要とされていた. 本稿ではBRAF変異陽性大腸癌の特徴, 治療開発, そして新たな治療戦略について概説するとともに, BRAFV600E変異陽性の治癒切除不能な進行・再発の大腸癌に対して有効性が認められたエンコラフェニブ(BRAF阻害剤), ビニメチニブ(MEK阻害剤), セツキシマブ(抗EGFR抗体)併用療法の大規模前向き臨床試験「BEACON CRC試験」の結果を紹介する. |
| Practice | 臨床医学：一般 |
| Keywords | BRAF V600E-mutated colorectal cancer, Encorafenib plus binimetinib plus cetuximab, BEACON CRC |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) MEBGEN RASKET(TM)-Bキット添付文書. 第4版, 2020年11月.
- 2) 大腸癌研究会/編: 大腸癌治療ガイドライン. 医師用2019年版, 金原出版, 東京, 2019.
- 3) キイトルーダ点滴静注100mg添付文書. 第4版, 2021年1月改訂.
- 4) オプジーボ点滴静注20mg/オプジーボ点滴静注100mg/オプジーボ点滴静注120mg/オプジーボ点滴静注240mg添付文書. 第5版, 2020年11月改訂.
- 5) ヤーボイ点滴静注液50mg添付文書. 第2版(効能変更, 用法変更), 2020年11月改訂.
残りの40件を表示する
- 6) ビラフトビカプセル50mg/ビラフトビカプセル75mg添付文書. 第1版(効能変更, 用法変更, 用量変更), 2020年11月改訂.
- 7) 公益社団法人日本臨床腫瘍学会/編: 大腸がん診療における遺伝子関連検査等のガイダンス. 第4版, 金原出版, 東京, 2019, p18.
- 8) Luu LJ and Price TJ: BRAF mutation and its impor-tance in colorectal cancer. Advances in the Molecular Understanding of Colorectal Cancer, IntechOpen, Lon-don, 2019.
- 9) Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of meta-static spread and prognosis in metastatic colorectal cancer. Cancer 117(20): 4623-4632, 2011.
- 10) De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemother-apy-refractory metastatic colorectal cancer: a retro-spective consortium analysis. Lancet Oncol 11(8): 753-762, 2010.
- 11) Tveit KM, Guren T, Glimelius B, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin(Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30(15): 1755-1762, 2012.
- 12) Sorbye H, Dragomir A, Sundstrom M, et al: High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective popula-tion-based metastatic colorectal cancer cohort. PLoS One 10(6): e0131046, 2015.
- 13) Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5): 856-862, 2011.
- 14) Nakanishi R, Harada J, Tuul M, et al: Prognostic rele-vance of KRAS and BRAF mutations in Japanese pa-tients with colorectal cancer. Int J Clin Oncol 18(6): 1042-1048, 2013.
- 15) Kawazoe A, Shitara K, Fukuoka S, et al: A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japa-nese patients with metastatic colorectal cancer. BMC Cancer 15: 258, 2015.
- 16) Chen D, Huang JF, Liu K, et al: BRAFV600E mutation and its association with clinicopathological features of col-orectal cancer: a systematic review and meta-analysis. PLoS One 9(3): e90607, 2014.
- 17) Ardekani GS, Jafarnejad SM, Tan L, et al: The prognos-tic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7(10): e47054, 2012.
- 18) Modest DP, Ricard I, Heinemann V, et al: Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27(9): 1746-1753, 2016.
- 19) Cremolini C, Loupakis E, Antoniotti C, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevaci-zumab as first-line treatment of patients with meta-static colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13): 1306-1315, 2015.
- 20) 島田安博: I. 切除不能大腸癌のフロントライン(1st). 日本大腸肛門病会誌 71(10): 371-379, 2018.
- 21) Cremolini C, Antoniotti C, Stein A, et al: Individual patient data meta-analysis of FOLFOXIRI plus bevaci-zumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol 38(28): 3314-3324, 2020.
- 22) Mitani S, Taniguchi H, Sugiyama K, et al: The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. Ther Adv Med Oncol 11: 2019. doi:10.1177/1758835918820298
- 23) Yang H, Higgins B, Kolinsky K, et al: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3): 779-789, 2012.
- 24) ビラフトビカプセル50mg/ビラフトビカプセル75mg医薬品インタビューフォーム. 第4版, 2020年11月改訂.
- 25) Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33(34): 4032-4038, 2015.
- 26) Long GV, Stroyakovskiy D, Gogas H, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, dou-ble-blind, phase 3 randomised controlled trial. Lancet 386(9992): 444-451, 2015.
- 27) Dummer R, Ascierto PA, Gogas HJ, et al: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma(COLUMBUS): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 19(5): 603-615, 2018.
- 28) Dummer R, Ascierto PA, Gogas HJ, et al: Overall sur-vival in patients with BRAF-mutant melanoma receiv-ing encorafenib plus binimetinib versus vemurafenib or encorafenib(COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(10): 1315-1327, 2018.
- 29) Corcoran RB, Dias-Santagata D, Bergethon K, et al: BRAF gene amplification can promote acquired resis-tance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3(149): ra84, 2010.
- 30) Corcoran RB, Atreya CE, Falchook GS, et al: Combined BRAF and MEK inhibition with dabrafenib and trame-tinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33(34): 4023-4031, 2015.
- 31) Lito P, Pratilas CA, Joseph EW, et al: Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E mel-anomas. Cancer Cell 22(5): 668-682, 2012.
- 32) Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feed-back activation of EGFR. Nature 483(7387): 100-103, 2012.
- 33) Corcoran RB, Andre T, Atreya CE, et al: Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 8(4): 428-443, 2018.
- 34) Mao M, Tian F, Mariadason JM, et al: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19(3): 657-667, 2013.
- 35) van Geel RMJM, Tabernero J, Elez E, et al: A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 7(6): 610-619, 2017.
- 36) Kawakami H, Huang S, Pal K, et al: Mutant BRAF up-regulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther 15(12): 3015-3027, 2016.
- 37) Zhang P, Kawakami H, Liu W, et al: Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF-mutant human colorectal cancer. Mol Cancer Res 16(3): 378-389, 2018.
- 38) Kopetz S, Guthrie KA, Morris VK, et al: Randomized trial of irinotecan and cetuximab with or without vemu-rafenib in BRAF-mutant metastatic colorectal cancer(SWOG S1406). J Clin Oncol 39(4): 285-294, 2021.
- 39) Kopetz S, Grothey A, Yaeger R, et al: Encorafenib, bini-metinib, and cetuximab in BRAF V600E-mutated col-orectal cancer. N Engl J Med 381(17): 1632-1643, 2019.
- 40) Grothey A, Tabernero J, Taieb J, et al: LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, bini-metinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol 31(S3): S242-243, 2020.
- 41) Carnahan J, Beltran PJ, Babij C, et al: Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 9(8): 2399-2410, 2010.
- 42) Hatzivassiliou G, Song K, Yen I, et al: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287): 431-435, 2010.
- 43) Gibney GT, Messina JL, Fedorenko IV, et al: Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10(7): 390-399, 2013.
- 44) ビラフトビカプセル50mg/ビラフトビカプセル75mg審議結果報告書. 2020年11月6日.
- 45) 大腸癌研究会/編: ガイドライン関連の最新情報. 大腸癌治療ガイドライン医師用2019年版の「切除不能進行再発大腸癌に対する薬物療法」に追記すべきエビデンス〜BRAF遺伝子変異を有する大腸癌に対するエンコラフェニブ+ビニメチニブ+セツキシマブ療法, エンコラフェニブ+セツキシマブ療法(2020年11月). http://www.jsccr.jp/guideline/news/202011_03.html
